[ad_1]
Photo by Dado Ruvic (Reuters / Scanpix)
Pfizer has launched its COVID-19 vaccine delivery program in four states in the US The drug’s manufacturer has suggested ways to solve distribution problems, as the drug can only be transported at very low temperatures.
Importantly, while the results of clinical trials with Pfizer and BioNTech are not optimistic that the world will eventually emerge from the pandemic, experts warn that caution must be exercised so far, as vaccines have a long way to go.
One problem is that a vaccine with a potency of more than 90% must be transported and stored at -70 degrees Celsius, well below other poor vaccines that can be stored at 2-8 ° C.
Pfizer has chosen Rhodes, Texas, New Mexico, and Tennessee for its distribution pilot program, taking into account differences in size, population diversity, and different opportunities to reach residents in diverse urban and rural areas. However, this is only a pilot project, and according to Reuters, the state population will not start vaccination earlier than in other states.
The results of the vaccine administration trial are expected to serve as a model for other states and other governments that are preparing to implement effective vaccination programs against COVID-19, announces the drug manufacturer.
Vaccination is expected next year
Pfizer and BioNTech have $ 1.95 billion with the US government USD from the contract, which must contribute 100 million. doses of vaccine and promises to provide another 500 million euros if necessary. dose.
The companies hope to have sufficient data on the safety of the late-stage trial vaccine when emergency clearance is requested by the end of November.
Previously, Pfizer and BioNTech announced that they could produce up to 50 million by the end of the year. vaccine dose. Another 1,300 million. doses in 2021.
The European Commission has announced a contract with Pfizer and BioNTech to buy 200 million. doses of ios vaccine with the possibility of ordering another 100 million. dose.
According to the preliminary agreement, Lithuania will have 1.24 million. dose of this vaccine.
A person needs two doses of the Pfizer vaccine.
On Monday it was announced that the American biotechnology company Moderna completed clinical trials in three phases, which is 94.5% effective. The company claims that its vaccine will remain suitable for use for 30 days at 2-8C and for 6 months. will remain effective when stored at -20 ° C.
Rayti komentar
[ad_2]
